148 related articles for article (PubMed ID: 38683590)
21. A new treatment for human malignant melanoma targeting L-type amino acid transporter 1 (LAT1): a pilot study in a canine model.
Fukumoto S; Hanazono K; Fu DR; Endo Y; Kadosawa T; Iwano H; Uchide T
Biochem Biophys Res Commun; 2013 Sep; 439(1):103-8. PubMed ID: 23954667
[TBL] [Abstract][Full Text] [Related]
22. Pharmacologic inhibition of LAT1 predominantly suppresses transport of large neutral amino acids and downregulates global translation in cancer cells.
Nishikubo K; Ohgaki R; Okanishi H; Okuda S; Xu M; Endou H; Kanai Y
J Cell Mol Med; 2022 Oct; 26(20):5246-5256. PubMed ID: 36071551
[TBL] [Abstract][Full Text] [Related]
23. Tyrosine-Chlorambucil Conjugates Facilitate Cellular Uptake through L-Type Amino Acid Transporter 1 (LAT1) in Human Breast Cancer Cell Line MCF-7.
Pocasap P; Weerapreeyakul N; Timonen J; Järvinen J; Leppänen J; Kärkkäinen J; Rautio J
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32244913
[TBL] [Abstract][Full Text] [Related]
24. Transport of 3-fluoro-L-α-methyl-tyrosine by tumor-upregulated L-type amino acid transporter 1: a cause of the tumor uptake in PET.
Wiriyasermkul P; Nagamori S; Tominaga H; Oriuchi N; Kaira K; Nakao H; Kitashoji T; Ohgaki R; Tanaka H; Endou H; Endo K; Sakurai H; Kanai Y
J Nucl Med; 2012 Aug; 53(8):1253-61. PubMed ID: 22743251
[TBL] [Abstract][Full Text] [Related]
25. Characterization of the system L amino acid transporter in T24 human bladder carcinoma cells.
Kim DK; Kanai Y; Choi HW; Tangtrongsup S; Chairoungdua A; Babu E; Tachampa K; Anzai N; Iribe Y; Endou H
Biochim Biophys Acta; 2002 Sep; 1565(1):112-21. PubMed ID: 12225859
[TBL] [Abstract][Full Text] [Related]
26. LAT1 acts as a crucial transporter of amino acids in human thymic carcinoma cells.
Hayashi K; Jutabha P; Maeda S; Supak Y; Ouchi M; Endou H; Fujita T; Chida M; Anzai N
J Pharmacol Sci; 2016 Nov; 132(3):201-204. PubMed ID: 27567475
[TBL] [Abstract][Full Text] [Related]
27. L-type amino acid transporter 1 (LAT1)-utilizing efflux transporter inhibitors can improve the brain uptake and apoptosis-inducing effects of vinblastine in cancer cells.
Montaser A; Markowicz-Piasecka M; Sikora J; Jalkanen A; Huttunen KM
Int J Pharm; 2020 Aug; 586():119585. PubMed ID: 32599132
[TBL] [Abstract][Full Text] [Related]
28. Molecular characteristics supporting l-Type amino acid transporter 1 (LAT1)-mediated translocation.
Kärkkäinen J; Laitinen T; Markowicz-Piasecka M; Montaser A; Lehtonen M; Rautio J; Gynther M; Poso A; Huttunen KM
Bioorg Chem; 2021 Jul; 112():104921. PubMed ID: 33933805
[TBL] [Abstract][Full Text] [Related]
29. The Regulation and Function of the L-Type Amino Acid Transporter 1 (LAT1) in Cancer.
Salisbury TB; Arthur S
Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30103560
[TBL] [Abstract][Full Text] [Related]
30. Imaging the L-type amino acid transporter-1 (LAT1) with Zr-89 immunoPET.
Ikotun OF; Marquez BV; Huang C; Masuko K; Daiji M; Masuko T; McConathy J; Lapi SE
PLoS One; 2013; 8(10):e77476. PubMed ID: 24143237
[TBL] [Abstract][Full Text] [Related]
31. Clinical significance of L-type amino acid transporter 1 expression as a prognostic marker and potential of new targeting therapy in biliary tract cancer.
Kaira K; Sunose Y; Ohshima Y; Ishioka NS; Arakawa K; Ogawa T; Sunaga N; Shimizu K; Tominaga H; Oriuchi N; Itoh H; Nagamori S; Kanai Y; Yamaguchi A; Segawa A; Ide M; Mori M; Oyama T; Takeyoshi I
BMC Cancer; 2013 Oct; 13():482. PubMed ID: 24131658
[TBL] [Abstract][Full Text] [Related]
32. L-type amino acid transporter 1 is associated with chemoresistance in breast cancer via the promotion of amino acid metabolism.
Sato M; Harada-Shoji N; Toyohara T; Soga T; Itoh M; Miyashita M; Tada H; Amari M; Anzai N; Furumoto S; Abe T; Suzuki T; Ishida T; Sasano H
Sci Rep; 2021 Jan; 11(1):589. PubMed ID: 33436954
[No Abstract] [Full Text] [Related]
33. Correlation of L-methyl-11C-methionine (MET) uptake with L-type amino acid transporter 1 in human gliomas.
Okubo S; Zhen HN; Kawai N; Nishiyama Y; Haba R; Tamiya T
J Neurooncol; 2010 Sep; 99(2):217-25. PubMed ID: 20091333
[TBL] [Abstract][Full Text] [Related]
34. Impact of system L amino acid transporter 1 (LAT1) on proliferation of human ovarian cancer cells: a possible target for combination therapy with anti-proliferative aminopeptidase inhibitors.
Fan X; Ross DD; Arakawa H; Ganapathy V; Tamai I; Nakanishi T
Biochem Pharmacol; 2010 Sep; 80(6):811-8. PubMed ID: 20510678
[TBL] [Abstract][Full Text] [Related]
35. L-type amino acid transporter 1, LAT1, in growth hormone-producing pituitary tumor cells.
Satou M; Wang J; Nakano-Tateno T; Teramachi M; Suzuki T; Hayashi K; Lamothe S; Hao Y; Kurata H; Sugimoto H; Chik C; Tateno T
Mol Cell Endocrinol; 2020 Sep; 515():110868. PubMed ID: 32579901
[TBL] [Abstract][Full Text] [Related]
36. Proteomics and phosphoproteomics reveal key regulators associated with cytostatic effect of amino acid transporter LAT1 inhibitor.
Okanishi H; Ohgaki R; Okuda S; Endou H; Kanai Y
Cancer Sci; 2021 Feb; 112(2):871-883. PubMed ID: 33264461
[TBL] [Abstract][Full Text] [Related]
37. L-type amino acid transporter 1 utilizing prodrugs of ferulic acid revealed structural features supporting the design of prodrugs for brain delivery.
Puris E; Gynther M; Huttunen J; Auriola S; Huttunen KM
Eur J Pharm Sci; 2019 Mar; 129():99-109. PubMed ID: 30625368
[TBL] [Abstract][Full Text] [Related]
38. Targeting L-type amino acid transporter 1 in urological malignancy: Current status and future perspective.
Pae S; Sakamoto S; Zhao X; Saito S; Tamura T; Imamura Y; Sazuka T; Reien Y; Hirayama Y; Hashimoto H; Kanai Y; Ichikawa T; Anzai N
J Pharmacol Sci; 2022 Dec; 150(4):251-258. PubMed ID: 36344047
[TBL] [Abstract][Full Text] [Related]
39. Comparison of Experimental Strategies to Study l-Type Amino Acid Transporter 1 (LAT1) Utilization by Ligands.
Huttunen J; Agami M; Tampio J; Montaser AB; Huttunen KM
Molecules; 2021 Dec; 27(1):. PubMed ID: 35011270
[TBL] [Abstract][Full Text] [Related]
40. Distribution of LAT1-targeting PET tracer was independent of the tumor blood flow in rat xenograft models of C6 glioma and MIA PaCa-2.
Aoki M; Watabe T; Nagamori S; Naka S; Ikeda H; Kongpracha P; Horitsugi G; Kanai Y; Shimosegawa E; Kanai Y; Hatazawa J
Ann Nucl Med; 2019 Jun; 33(6):394-403. PubMed ID: 30820863
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
